logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Hester Biosciences Ltd

Hester Biosciences

Small Cap•642 Employees•IPO 1994
Current Price
₹1401.50
-14.5 (-1.02%)Updated
NSE :HESTERBIO
BSE :524669
Sector :Biotechnology
Today's Range
1391
₹1401.50
indicator
1440
52 Week Range
52W Low₹1242.95
52W High₹2350.00
₹1401.50
indicator
Downside12.76%
Upside67.68%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹1,333.03 Cr
Market Cap
Total market value of company
P/E Ratio
32.55
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
4.83
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹37.69
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
4.83%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
9.71%
ROCE
Return on Capital Employed. >15% is good
Net Margin
13.02%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-1.20%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
11.16%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
2.24%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
159.00%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.68
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹369.41
Book Value
Net asset value per share
Dividend Yield
0.45%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
53.70%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

3 points
  • •Hester Biosciences exhibits a robust operating profit margin (OPM) of 21.20%, showcasing efficient cost management and strong pricing power within its industry. This indicates a resilient business model capable of generating substantial profits even amidst market fluctuations.
  • •The company's promoter holding stands at a strong 53.7%, signifying considerable confidence in the company's future trajectory. This high promoter stake often translates to better corporate governance and long-term strategic planning, potentially boosting shareholder value.

Weaknesses

5 points
  • •Hester Biosciences' high price-to-earnings (PE) ratio of 36.60 suggests the stock may be overvalued relative to its earnings. Investors should carefully evaluate future growth prospects to justify this premium valuation and mitigate potential losses from market corrections.
  • •The company's debt-to-equity ratio of 0.68 indicates a moderate level of financial leverage. While not excessively high, this debt could amplify financial risk during economic downturns or periods of reduced profitability, potentially limiting financial flexibility.

Opportunities

3 points
  • •The broader Pharmaceuticals and Healthcare sector often benefits from increasing global health awareness, rising demand for vaccines and animal health products, and advancements in medical research, presenting growth avenues for Hester Biosciences.
  • •With a relatively smaller market capitalization of 1376 Cr compared to industry giants, Hester Biosciences has substantial room for market share expansion and scaling operations, potentially attracting new institutional investments.

Threats

4 points
  • •Hester Biosciences faces intense competition from larger, well-established players in the Pharmaceuticals sector, such as Sun Pharma and Cipla. This competitive landscape could pressure pricing, market share, and overall profitability margins.
  • •The highly regulated nature of the pharmaceutical industry poses a significant threat. Adverse changes in government policies, drug pricing controls, or stringent regulatory approvals could negatively impact operations and future revenue streams.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹1528.67+₹127.17+9.07%
R3₹1479.67+₹78.17+5.58%
R2₹1459.83+₹58.33+4.16%
R1₹1430.67+₹29.17+2.08%
PIVOT₹1410.839.330.67%
CURRENT₹1401.50--
S1₹1283.67-₹117.83-8.41%
S2₹1332.67-₹68.83-4.91%
S3₹1361.83-₹39.67-2.83%
S4₹1381.67-₹19.83-1.42%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.09L
(18 Mar 2026)
+93.4% vs avg
Delivery %
73.8%
(18 Mar 2026)
+7.7% vs avg
Avg Volume (20D)
0.05L
(18 Feb - 18 Mar)
20-day average
Avg Delivery %
66.1%
(18 Feb - 18 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Biocon Ltd
61,453.63 ₹ Cr
Best Profit Growth
Panacea Biotec Ltd
74.80 %
Highest Dividend Yield
Biocon Ltd
0.15 %

Peer Comparison

Company Name
BIOCON
Biocon Ltd
PANACEABIO
Panacea Biotec Ltd

About

HESTERBIO

Hester Biosciences Ltd

Hester Biosciences Limited is a prominent Indian company specializing in the manufacturing and trading of veterinary vaccines and animal health products, both domestically and internationally. Their business model is segmented into three key areas: Poultry Healthcare, Animal Healthcare, and Petcare, each contributing significantly to their overall revenue and market presence.

The Poultry Healthcare segment forms a substantial portion of Hester's business, focusing on the production and distribution of a wide range of vaccines targeted at various poultry diseases. These vaccines combat common and serious illnesses affecting poultry flocks, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, Marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. This comprehensive suite of vaccines addresses a significant need within the Indian and international poultry industries, ensuring the health and productivity of poultry farms.

Beyond poultry, Hester's Animal Healthcare segment extends its reach to livestock, providing vaccines to protect against diseases such as goat pox, peste des petits ruminants, brucella abortus, contagious bovine pleuropneumonia (CBPP), and lumpy skin disease. In addition to vaccines, this segment offers a diverse range of animal healthcare products, encompassing biosecurity solutions, therapeutic treatments, herbal supplements, homeopathic remedies, and feed supplements. This integrated approach aims to provide comprehensive health management solutions for livestock farmers.

Finally, Hester's Petcare segment caters to the growing market for pet health products. They offer a variety of formulations addressing various pet health needs, including gut health solutions, NSAIDs for pain relief, joint care formulations, parasiticides, coat nutrition products, grooming aids, and anti-infective treatments. This segment reflects Hester's commitment to expanding its product portfolio to encompass the needs of a broadening consumer base.

Further augmenting its services, Hester Biosciences provides diagnostic services, including seroprofiling kits and operates diagnostic labs specifically for poultry flocks. They also offer specialized programs, such as mastitis control programs for cattle, demonstrating a commitment to proactive health management and disease prevention. In essence, Hester Biosciences acts not only as a manufacturer and trader but also as a provider of comprehensive animal health solutions across various segments of the market, reflecting a vertically integrated business model.

COMPANY FACTS - HESTERBIO

Registered Address

Pushpak 1st Floor, Motilal Hirabhai Road, Panchvati Circle

Ahmedabad

GUJARAT

IN

Tel: 917926445107

Website:https://www.hester.in/

Investor Relations:http://www.hester.in/investor-relation/
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Biotechnology

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 642

IPO Date: 17/08/1994

MANAGEMENT - HESTERBIO

Dr. Bhupendra Gandhi

Non-Executive Chairman of the Board

Mr. Rajiv Gandhi

Chief Executive Officer, Managing Director, Executive Director

Mr. Divyesh Maru

Chief Financial Officer

Mr. Vinod Mali

Compliance Officer, Company Secretary

Ms. Priya Gandhi

Executive Director

Ms. Nina Gandhi

Non-Executive Director

Mr. Ravin Gandhi

Non-Executive Director

Mr. Sanjiv Gandhi

Non-Executive Director

Mr. Ashok Bhadakal

Non-Executive Independent Director

Mr. Ameetkumar Desai

Non-Executive Independent Director

Mr. Anil Jain

Non-Executive Independent Director

Ms. Sandhya Patel

Non-Executive Independent Director

Investor Questions Answered

Hester Biosciences Ltd (HESTERBIO) Stock FAQs

Get answers to the most common questions about Hester Biosciences Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Hester Biosciences Ltd (HESTERBIO) is ₹1,401.5. Today, the stock has declined by ₹14.50 (1.02%), trading in a range of ₹1,391 to ₹1,440. The stock opened at ₹1,420 with a trading volume of 9,050 shares.
Hester Biosciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,333.03 crores, P/E ratio of 32.55, ROE of 4.83%, and ROCE of 9.71%. The dividend yield stands at 0.45%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Hester Biosciences Ltd (HESTERBIO) is ₹2,350, while the 52-week low is ₹1,242.95. Currently trading at ₹1,401.5, the stock is 14.3% away from its 52-week low and 40.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Hester Biosciences Ltd stock at ₹1,401.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 32.55 and P/B ratio of N/A. Today's performance shows a loss of 1.02%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Hester Biosciences Ltd offers a dividend yield of 0.45%, which means for every ₹100 invested at the current price of ₹1,401.5, you can expect to receive approximately ₹0.45 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Hester Biosciences Ltd's key financial metrics include: P/E Ratio: 32.55, P/B Ratio: N/A, ROE: 4.83%, ROCE: 9.71%, Dividend Yield: 0.45%, EPS: ₹37.69, Book Value: ₹369.41, Debt-to-Equity: 0.68, and Current Ratio: N/A. The company's market cap stands at ₹1,333.03 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Hester Biosciences Ltd stock opened at ₹1,420 and is currently trading at ₹1,401.5, showing a decline of ₹14.50 (1.02%). The intraday high is ₹1,440 and low is ₹1,391. The trading volume stands at 9,050 shares, indicating moderate market participation today.
Hester Biosciences Ltd has a Price-to-Earnings (P/E) ratio of 32.55, which means investors are willing to pay ₹32.55 for every ₹1 of earnings. With an EPS of ₹37.69, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Hester Biosciences Ltd has a market capitalization of ₹1,333.03 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,401.5) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Hester Biosciences Ltd has a book value of ₹369.41 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,401.5, which is 279.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Hester Biosciences Ltd has a Return on Equity (ROE) of 4.83% and Return on Capital Employed (ROCE) of 9.71%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Hester Biosciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Hester Biosciences Ltd has a debt-to-equity ratio of 0.68, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Hester Biosciences Ltd has an Earnings Per Share (EPS) of ₹37.69, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,401.5 and P/E ratio of 32.55, investors are paying 32.55 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Hester Biosciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Hester Biosciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Hester Biosciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (32.55), ROE (4.83%), debt-to-equity (0.68), and growth rates. 2) Technical Analysis - Check 52-week range (₹1242.95 - ₹2350.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1401.50) with book value (₹369.41) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Hester Biosciences Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,401.5 is 13915x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Hester Biosciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1242.95 - ₹2350.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.68 indicates leverage. 4) Liquidity Risk - Based on trading volume of 9,050 shares. 5) Valuation Risk - P/E of 32.55 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Hester Biosciences Ltd operates in the industry with key metrics: P/E ratio of 32.55, ROE of 4.83%, market cap of ₹1,333.03 crores, and dividend yield of 0.45%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.68), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Hester Biosciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,401.5, with a 52-week range of ₹1242.95 to ₹2350.00. Based on fundamentals like P/E (32.55), ROE (4.83%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Hester Biosciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1401.50. 2) Fundamental Deterioration - Declining ROE (currently 4.83%), increasing debt (D/E: 0.68), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Hester Biosciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.45%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.